Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE
IGF-1 LR3 provides a powerful, direct, and localized anabolic signal
By the end of the trial, 23 of the 102 participants assigned to treatment dropped out of the study (compared to only 15 dropouts on placebo.) Many taking the drug complained of nausea, one of the most common side effects of GLP-1 drugs, which work to regulate blood sugar, and end up slowing down digestion
We had our hands in the soil, dirt under our fingernails
These converging pathways ultimately enhance cardiomyocyte survival
Most-recommended for new GLP-1 users